HYMOVIS® Demonstrates Superior Biomechanical Lubricating Properties
HYMOVIS® has exceptional lubricating properties in moving cartilage to a low-friction regime. The study provides a unifying framework to evaluate the potential clinical efficacy of injectable hyaluronic acid therapies
PARSIPPANY, NJ., March 22, 2017 - Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA) - based products and its
HYMOVIS® Receives Permanent, Product-Specific J-Code from the Centers for Medicare and Medicaid Services (CMS)
PARSIPPANY, NJ.(BUSINESS WIRE)— Fidia Pharma USA Inc., a wholly owned subsidiary of Fidia Farmaceutici S.p.A. a worldwide leader in the research development and manufacturing of HA based products, has announced that the Center for Medicare & Medicaid Services ("CMS") has assigned its product HYMOVIS® a unique Healthcare Common Procedure Coding System ("HCPCS") code, or J-Code.
Fidia Presents New Data on Hymovis® , a Breakthrough in Viscoelastic Technology, at the American Orthopaedic Society for Sports Medicine 2016 Annual Meeting
Hymovis® is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties; new data demonstrating long-term benefits of Hymovis® in alleviating osteoarthritis knee pain and stiffness and improving physical function and quality of life will be presented.
PARSIPPANY, N.J., July 5, 2016 – Fidia Farmaceutici S.p.A., a world leader